EMD Millipore Receives Recertification of GMP Compliance for Biodevelopment Centre - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMD Millipore Receives Recertification of GMP Compliance for Biodevelopment Centre



EMD Millipore reported that its Biodevelopment Centre in Martillac, France, has been recertified by the French National Agency for Medicines and Health Products Safety, the competent authority of France. The certification confirms the 3440 m2 facility complies with the principles of GMP for active substances. The audit included a thorough review of quality systems, supplier management, control of raw materials, documentation, calibration and validation. Prior certification consisted only of stainless steel equipment, while this recertification included complete single-use upstream and downstream suites, as well as a 2 x 1250 L stainless steel suite.

EMD Millipore's Provantage biodevelopment and clinical supply services are delivered at the Martillac, France facility. This approach for biologics manufacturing incorporates technologies in upstream, downstream and single-use systems. This Provantage offering includes process development and GMP drug substance for pre-clinical to Phase II and is available to a global customer base.

Source: EMD Millipore

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here